
Harrow, Inc. (NASDAQ:HROW – Free Report) – Research analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Harrow in a research report issued on Wednesday, November 11th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.40) per share for the year, up from their prior estimate of ($0.57). The consensus estimate for Harrow’s current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Harrow’s Q2 2027 earnings at ($0.10) EPS, Q4 2027 earnings at $0.92 EPS and FY2027 earnings at $0.50 EPS.
Harrow (NASDAQ:HROW – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.06. Harrow had a negative net margin of 9.39% and a negative return on equity of 69.81%. The company had revenue of $99.30 million for the quarter, compared to analyst estimates of $98.59 million.
A number of other analysts have also recently commented on HROW. BTIG Research reaffirmed a “buy” rating and set a $63.00 price target on shares of Harrow in a research report on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research report on Friday, October 16th. Wall Street Zen raised Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research downgraded Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 3rd. Finally, Leerink Partners assumed coverage on Harrow in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $66.20.
Read Our Latest Stock Analysis on HROW
Harrow Trading Down 3.6%
Shares of NASDAQ HROW opened at $28.30 on Friday. The company has a debt-to-equity ratio of 10.15, a current ratio of 2.29 and a quick ratio of 2.08. Harrow has a twelve month low of $25.76 and a twelve month high of $54.85. The firm has a fifty day simple moving average of $30.94 and a 200 day simple moving average of $37.59.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of HROW. BlackRock Inc. bought a new position in Harrow during the second quarter worth $116,373,000. Bamco Inc. NY bought a new stake in Harrow in the second quarter valued at $34,373,000. Jupiter Topco LLC acquired a new position in shares of Harrow during the second quarter valued at about $24,596,000. Rice Hall James & Associates LLC acquired a new position in shares of Harrow during the second quarter valued at about $16,459,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Harrow by 56.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock worth $20,428,000 after purchasing an additional 208,972 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.
Harrow Company Profile
Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.
Read More
- Five stocks we like better than Harrow
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
